Once weekly dulaglutide therapy in type 2 diabetic subjects, real-world evidence from a tertiary care diabetes center in India
Aims: To evaluate the real-world efficacy, durability, and side-effect profile of once weekly GLP1RA: dulaglutide in Indian type 2 diabetes mellitus (T2DM) patients. Materials and Methods: A retrospective observational study. Data for efficacy (HbA1c and weight), adherence/discontinuation and patien...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
| Series: | Indian Journal of Endocrinology and Metabolism |
| Subjects: | |
| Online Access: | http://www.ijem.in/article.asp?issn=2230-8210;year=2018;volume=22;issue=6;spage=728;epage=734;aulast=Wasir |
| _version_ | 1811212601983500288 |
|---|---|
| author | Jasjeet S Wasir Ambrish Mithal Paras Agarwal Apeksha Mittal |
| author_facet | Jasjeet S Wasir Ambrish Mithal Paras Agarwal Apeksha Mittal |
| author_sort | Jasjeet S Wasir |
| collection | DOAJ |
| description | Aims: To evaluate the real-world efficacy, durability, and side-effect profile of once weekly GLP1RA: dulaglutide in Indian type 2 diabetes mellitus (T2DM) patients. Materials and Methods: A retrospective observational study. Data for efficacy (HbA1c and weight), adherence/discontinuation and patient reported side-effects, of 117 patients who were prescribed dulaglutide were analyzed. Results: Final analysis was done on complete data of 74 patients (6 months follow-up), this indicated that dulaglutide is effective (mean-reduction at 6 months of: HbA1c; 0.87% and weight; 3.8 kg). Subjects with a poorer glycemic control (greater HbA1c) or greater weight at initiation had a better fall in HbA1c and weight reduction at the end of the study. The most common side-effects were gastrointestinal (15% nausea and 6% loose motions). Also, 25% (n = 19) of our study subjects discontinued dulaglutide because of gastrointestinal side-effects. Conclusion: Our real-world experience is well aligned to systematic data of the randomized controlled trials (RCTs) regarding the efficacy of dulaglutide in the treatment of T2DM (our study vs. RCTs; HbA1c reduction: 0.87% vs. 0.78% to 1.64%, weight reduction: 3.8 vs. 0.3 to 3 kg). The most common side-effects and reason for discontinuation were gastrointestinal side-effects. Finally, by virtue of their observed benefit, we expect a superior cardiovascular risk-reduction with dulaglutide use in our population. |
| first_indexed | 2024-04-12T05:31:50Z |
| format | Article |
| id | doaj.art-f7490611c90b4a6591db485e765fb992 |
| institution | Directory Open Access Journal |
| issn | 2230-8210 |
| language | English |
| last_indexed | 2024-04-12T05:31:50Z |
| publishDate | 2018-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Endocrinology and Metabolism |
| spelling | doaj.art-f7490611c90b4a6591db485e765fb9922022-12-22T03:46:02ZengWolters Kluwer Medknow PublicationsIndian Journal of Endocrinology and Metabolism2230-82102018-01-0122672873410.4103/ijem.IJEM_424_18Once weekly dulaglutide therapy in type 2 diabetic subjects, real-world evidence from a tertiary care diabetes center in IndiaJasjeet S WasirAmbrish MithalParas AgarwalApeksha MittalAims: To evaluate the real-world efficacy, durability, and side-effect profile of once weekly GLP1RA: dulaglutide in Indian type 2 diabetes mellitus (T2DM) patients. Materials and Methods: A retrospective observational study. Data for efficacy (HbA1c and weight), adherence/discontinuation and patient reported side-effects, of 117 patients who were prescribed dulaglutide were analyzed. Results: Final analysis was done on complete data of 74 patients (6 months follow-up), this indicated that dulaglutide is effective (mean-reduction at 6 months of: HbA1c; 0.87% and weight; 3.8 kg). Subjects with a poorer glycemic control (greater HbA1c) or greater weight at initiation had a better fall in HbA1c and weight reduction at the end of the study. The most common side-effects were gastrointestinal (15% nausea and 6% loose motions). Also, 25% (n = 19) of our study subjects discontinued dulaglutide because of gastrointestinal side-effects. Conclusion: Our real-world experience is well aligned to systematic data of the randomized controlled trials (RCTs) regarding the efficacy of dulaglutide in the treatment of T2DM (our study vs. RCTs; HbA1c reduction: 0.87% vs. 0.78% to 1.64%, weight reduction: 3.8 vs. 0.3 to 3 kg). The most common side-effects and reason for discontinuation were gastrointestinal side-effects. Finally, by virtue of their observed benefit, we expect a superior cardiovascular risk-reduction with dulaglutide use in our population.http://www.ijem.in/article.asp?issn=2230-8210;year=2018;volume=22;issue=6;spage=728;epage=734;aulast=WasirDulaglutidereal-world experiencetype 2 diabetes mellitus |
| spellingShingle | Jasjeet S Wasir Ambrish Mithal Paras Agarwal Apeksha Mittal Once weekly dulaglutide therapy in type 2 diabetic subjects, real-world evidence from a tertiary care diabetes center in India Indian Journal of Endocrinology and Metabolism Dulaglutide real-world experience type 2 diabetes mellitus |
| title | Once weekly dulaglutide therapy in type 2 diabetic subjects, real-world evidence from a tertiary care diabetes center in India |
| title_full | Once weekly dulaglutide therapy in type 2 diabetic subjects, real-world evidence from a tertiary care diabetes center in India |
| title_fullStr | Once weekly dulaglutide therapy in type 2 diabetic subjects, real-world evidence from a tertiary care diabetes center in India |
| title_full_unstemmed | Once weekly dulaglutide therapy in type 2 diabetic subjects, real-world evidence from a tertiary care diabetes center in India |
| title_short | Once weekly dulaglutide therapy in type 2 diabetic subjects, real-world evidence from a tertiary care diabetes center in India |
| title_sort | once weekly dulaglutide therapy in type 2 diabetic subjects real world evidence from a tertiary care diabetes center in india |
| topic | Dulaglutide real-world experience type 2 diabetes mellitus |
| url | http://www.ijem.in/article.asp?issn=2230-8210;year=2018;volume=22;issue=6;spage=728;epage=734;aulast=Wasir |
| work_keys_str_mv | AT jasjeetswasir onceweeklydulaglutidetherapyintype2diabeticsubjectsrealworldevidencefromatertiarycarediabetescenterinindia AT ambrishmithal onceweeklydulaglutidetherapyintype2diabeticsubjectsrealworldevidencefromatertiarycarediabetescenterinindia AT parasagarwal onceweeklydulaglutidetherapyintype2diabeticsubjectsrealworldevidencefromatertiarycarediabetescenterinindia AT apekshamittal onceweeklydulaglutidetherapyintype2diabeticsubjectsrealworldevidencefromatertiarycarediabetescenterinindia |